Lanreotide acetate
Lanreotide acetate structure
|
Common Name | Lanreotide acetate | ||
|---|---|---|---|---|
| CAS Number | 127984-74-1 | Molecular Weight | 1156.375 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C56H73N11O12S2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Warning | |
|
[Drug therapy for acromegaly].
Orv. Hetil. 154(39) , 1527-34, (2013) Prolonged overproduction of growth hormone, like insulin-like growth factor-1 hypersecretion leads to acromegaly in adults. This is associated with several co-morbidities and increased mortality. Despite typical clinical features and modern diagnostic tools, ... |
|
|
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.
Pituitary 16(3) , 354-62, (2013) Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeletal growth, and increased risk of cardiovascular disease. Acr... |
|
|
Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
Ann. Endocrinol. (Paris.) 74(1) , 49-52, (2013) We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combinat... |
|
|
Merkel cell carcinoma of the auricle: a treacherous skin tumor.
J. Cancer Res. Ther. 8(3) , 460-2, (2012)
|
|
|
Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.
J. Clin. Oncol. 30(35) , 4290-1, (2012)
|
|
|
Carcinoid crisis induced by repeated abdominal examination.
Intern. Med. J. 42(3) , 342-4, (2012)
|
|
|
Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
J. Clin. Oncol. 30(35) , 4337-43, (2012) To investigate the somatostatin analog lanreotide as symptomatic treatment for inoperable bowel obstruction due to peritoneal carcinomatosis.In all, 80 patients with peritoneal carcinomatosis, inoperable malignant digestive obstruction, and two or more vomiti... |
|
|
Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
Horm. Res. Paediatr. 78(2) , 106-12, (2012) Medical treatment is a substantial therapeutic measure to achieve glycemic control and prevent hypoglycemic brain damage without surgery in patients with congenital hyperinsulinism (CHI). However, only few drugs are available and even fewer are approved as a ... |
|
|
Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
Clin. J. Oncol. Nurs. 16(1) , 56-64, (2012) Although neuroendocrine tumors (NETs) have been recognized as a family of complex malignancies since 1907, major progress has been made only in the past 20 years in understanding and managing the disease. The detection and reported incidence of NETs have incr... |
|
|
[Somatostatin and the digestive system. Clinical experiences].
Orv. Hetil. 154(39) , 1535-40, (2013) The effect of somatostatin on the gastrointestinal tract is complex; it inhibits the release of gastrointestinal hormones, the exocrine function of the stomach, pancreas and bile, decreases motility and influences absorption as well. Based on these diverse ef... |